Clinical Trials Logo

Recurrent Prostate Carcinoma clinical trials

View clinical trials related to Recurrent Prostate Carcinoma.

Filter by:

NCT ID: NCT03582774 Not yet recruiting - Clinical trials for Recurrent Prostate Carcinoma

Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]

Start date: July 30, 2018
Phase: Phase 3
Study type: Interventional

For men with a recurrence following radical prostatectomy, salvage external beam radiation therapy (SRT) can provide long-term disease control if the recurrence is encompassed within the treatment field and a sufficient radiation dose can be delivered to eradicate the residual/recurrent cancer. SRT offers long-term biochemical control in about 60% of patients. Target volume delineations for prostate cancer SRT after radical prostatectomy are usually drawn in the absence of visibly recurrent disease.

NCT ID: NCT03515577 Recruiting - Clinical trials for Recurrent Prostate Carcinoma

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery

PSMA vs AXUMIN
Start date: March 2, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial compares how well gallium 68-labeled PSMA-11 positron emission tomography/computed tomography (PET/CT) works compared to fluciclovine F18 PET/CT in imaging participants with prostate cancer after surgery that has come back. PET is an established imaging technique that uses small amounts of radioactivity and CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the body. Diagnostic procedures, such as PET/CT with gallium 68-labeled PSMA-11, may work better than PET/CT with fluciclovine F18 in helping find out how far the prostate cancer has spread.

NCT ID: NCT03501940 Available - Clinical trials for Prostate Adenocarcinoma

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such as fluorine F 18 DCFPyL PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.

NCT ID: NCT03123978 Recruiting - Clinical trials for Stage IV Prostate Cancer

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

Start date: January 9, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose and side effects of niclosamide when given together with enzalutamide in treating patients with castration-resistant prostate cancer that has come back or has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells. Niclosamide may block signals that enhance prostate cancer cell growth. Giving enzalutamide and niclosamide may work better in treating patients with castration-resistant prostate cancer.

NCT ID: NCT03122743 Recruiting - Clinical trials for Hormone-Resistant Prostate Cancer

Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer

Start date: February 20, 2017
Phase:
Study type: Observational

This pilot research trial studies the collection of serum samples in studying emotional stress in patients with prostate cancer. Studying serum samples from patients with prostate cancer in the laboratory may help doctors determine if levels of epinephrine and cortisol, substances the body makes when stressed, rise or fall with how patients are feeling and/or if those levels are related to clinical information related to prostate cancer.

NCT ID: NCT03016741 Recruiting - Clinical trials for Stage IV Prostate Cancer

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Start date: March 31, 2017
Phase: Phase 4
Study type: Interventional

This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. The investigators use MRI imaging (non-invasive, non-contrast) to see whether there are changes in brain structure or activity related to treatment that may be related to changes in cognitive function. The investigators are also looking for genetic variations that might make patients more or less sensitive to cognitive changes during treatment for prostate cancer.

NCT ID: NCT02985021 Recruiting - Clinical trials for Stage IV Prostate Cancer

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Start date: November 2016
Phase: Phase 2
Study type: Interventional

In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.

NCT ID: NCT02940262 Recruiting - Clinical trials for Prostate Adenocarcinoma

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Start date: September 5, 2016
Phase: N/A
Study type: Interventional

This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back in patients after initial therapy. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET/CT, may help doctors detect tumors that have come back after initial therapy.

NCT ID: NCT02935205 Recruiting - Clinical trials for Stage IV Prostate Cancer

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Start date: January 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects of enzalutamide and indomethacin and to see how well they work in treating patients with prostate cancer that does not respond to treatment with hormones, has come back, or has spread from where it started to other places in the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells.

NCT ID: NCT02899221 Recruiting - Clinical trials for Recurrent Prostate Carcinoma

Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation

Start date: March 21, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best way to give hyperthermia and high dose rate radiation therapy in treating patients with prostate cancer that has come back after prior radiation treatment. Radiation therapy, such as high dose rate brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Hyperthermia therapy may make tumor cells more sensitive to the effects of radiation therapy by heating them to several degrees above normal body temperature. Giving hyperthermia and high dose rate radiation therapy may work better in treating patients with recurrent prostate cancer after radiation.